Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Timothy L. Cannon"'
Autor:
Laura E. Johnston, Jamie Randall, Safae Chouraichi, Mary Luu, Allison L. Hunt, Lauren Mauro, Claudius Mueller, Justin B. Davis, Emanuel F. Petricoin, Thomas P. Conrads, Timothy L. Cannon, Jasmine Huynh
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-7 (2024)
Abstract Recent trials have shown the efficacy of trastuzumab deruxtecan (T-DXd) in HER2-negative patients, but there is not yet a way to identify which patients will best respond, especially with the inability of current HER2 IHC and FISH assays to
Externí odkaz:
https://doaj.org/article/62cf1a759ec3482aa0239484568040b5
Autor:
Allison L Hunt, Aratara Nutcharoen, Jamie Randall, Alyssa Papazian, John Deeken, G Larry Maxwell, Nicholas W Bateman, Emanuel F Petricoin, Amin Benyounes, Thomas P Conrads, Timothy L Cannon
Publikováno v:
The Oncologist.
Inflammatory myofibroblastic tumors (IMTs) are intermediate-grade mesenchymal neoplasms commonly characterized by chromosomal rearrangements causing constitutive activation of anaplastic lymphoma kinase (ALK) and/or ALK mutations causing reduced sens
Autor:
Mary Steimer, Jessica Leabo, Hongkun Wang, David Heyer, Nancy Bowles, Laura Matthews, Timothy L. Cannon, Raymund Cuevo, William B. Ershler, Danielle Shafer, Sekwon Jang, Angela Pennisi, Amjaad Al-Hussain, Kirby Farrell, John F. Deeken
Publikováno v:
Oncology Issues. 37:20-26
Autor:
Kelsey A, Klute, Michael, Rothe, Elizabeth, Garrett-Mayer, Pam K, Mangat, Reza, Nazemzadeh, Kathleen J, Yost, Herbert L, Duvivier, Eugene R, Ahn, Timothy L, Cannon, Olatunji B, Alese, John C, Krauss, Ramya, Thota, Carmen J, Calfa, Crystal S, Denlinger, Raegan, O'Lone, Susan, Halabi, Gina N, Grantham, Richard L, Schilsky
Publikováno v:
JCO precision oncology. 6
TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. The results of a cohort of patients with colorectal cancer
Autor:
Danielle Shafer, Kirby Farrell, Sekwon Jang, John F. Deeken, William B. Ershler, Amjaad Al-Hussain, Jessica Leabo, Timothy L. Cannon, Angela Pennisi, Mary Steimer, David Heyer, Raymund Cuevo, Nancy Bowles, Hongkun Wang, Nancy Addison
Publikováno v:
JCO Oncology Practice. 17:e1286-e1292
PURPOSE:The COVID-19 pandemic has posed significant challenges in the care of patients with cancer, including how to manage outpatients who are COVID-positive but do not require hospitalization. We explored the use of a remote patient monitoring (RPM
Autor:
Pam K. Mangat, Suanna S. Bruinooge, Timothy L. Cannon, Sagun Shrestha, Nicole L. Butler, Julie Gottlieb Fisher, Andrew L. Rygiel, Sasha L. Warren, Damien Hansra, Carmen Julia Calfa, Richard L. Schilsky, Ajjai Alva, Eugene R Ahn, Susan Halabi, Maged F. Khalil, Shamika Ranasinghe, Pamela A. Crilley, Elizabeth Garrett-Mayer, Kaitlyn R. Antonelli, Derrick S. Haslem
Publikováno v:
Journal of Clinical Oncology. 39:2443-2451
PURPOSE The TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. Results in a co
Autor:
Daniel Haggstrom, Pam K. Mangat, Susan Halabi, Ramya Thota, Anu G. Gaba, Kathryn B. Alguire, Elie G. Dib, Samiha Islam, Andrew L. Rygiel, Richard L. Schilsky, Elizabeth Garrett-Mayer, Eugene R Ahn, Kaitlyn R. Antonelli, Ashish Sangal, Pamela A. Crilley, Alissa S. Marr, Suanna S. Bruinooge, Carmen Julia Calfa, Timothy L. Cannon
Publikováno v:
JCO Precision Oncology. :757-766
PURPOSE The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known t
Autor:
Timothy L. Cannon, Ramya Thota, Nicole D. Fleming, Susan Halabi, Ricardo H. Alvarez, Jared Addison Cotta, Pam K. Mangat, Carmen Julia Calfa, Pamela A. Crilley, Sasha L. Warren, Andrew L. Rygiel, Theodore Pollock, Dan Veljovich, Elizabeth Garrett-Mayer, Julian C. Schink, Tareq Al Baghdadi, Julie Gottlieb Fisher, David Tait, Richard L. Schilsky
Publikováno v:
Targeted Oncology. 15:733-741
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study, a phase II basket study, evaluates anti-tumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known as drug target
Publikováno v:
Annals of Surgical Oncology. 27:2974-2982
Diffuse malignant peritoneal mesothelioma (DMPM) is a rare malignancy associated with poor outcomes. Recent reports have shown longer survival with radical surgery, usually combined with intraperitoneal chemotherapy. However, surgical interventions i
Autor:
Eugene R, Ahn, Pam K, Mangat, Elizabeth, Garrett-Mayer, Susan, Halabi, Elie G, Dib, Daniel E, Haggstrom, Kathryn B, Alguire, Carmen J, Calfa, Timothy L, Cannon, Pamela A, Crilley, Anu G, Gaba, Alissa S, Marr, Ashish, Sangal, Ramya, Thota, Kaitlyn R, Antonelli, Samiha, Islam, Andrew L, Rygiel, Suanna S, Bruinooge, Richard L, Schilsky
Publikováno v:
JCO precision oncology. 4
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known to be dru